Central nervous system metastases in epithelial ovarian carcinoma (original) (raw)
Related papers
To report involvement of the central nervous system (CNS) following epithelial ovarian cancer is rare. Advances in management of ovarian cancer by use of primary surgery including abdominal hysterectomy, bilateral salpingo'oophorectomy should attain as complete a cytoreduction as possible and effective platinum-based chemotherapy have prolonged survival. We present a case involving a 35-year-old Iranian woman diagnosed and treated for primary ovarian cancer in 2002. She underwent optimal cytoreductive surgery and chemotherapy treatment. Eight months after the initiation of therapy, multiple brain metastases without intraperitoneal lesions were found and treated with combination chemotherapy and whole brain radiotherapy (WBRT), without evidence of recurrent disease. The patient died from disease in December 2005. In a patient suffering from neoplasm that rarely metastasizes to CNS, a careful clinical examination and proper therapeutic approach including chemotherapy may lead to p...
Brain metastases from epithelial ovarian cancer: overview and optimal management
Anticancer research, 2009
Central nervous system involvement is a rare finding in the management of epithelial ovarian cancer with an incidence between 1-2%. A sharp rise in the incidence has been widely and repeatedly proclaimed for nearly two decades now, but has to be treated with scepticism after a careful review of the current literature. Brain metastases from ovarian cancer are known to be related to a very poor prognosis. Since brain imaging is not part of the routine follow-up care for ovarian cancer patients, and since CA-125--one of the standard tools--cannot be relied upon to detect central nervous system relapse, brain lesions are mostly traced by unspecific neurological symptoms only. Several prognostic factors are still being discussed today. But only a high performance status and the absence of an extra cranial disease at the time of CNS relapse have been accepted throughout the current literature as having a highly significant positive impact on survival. In the past, therapeutic efforts have...
International Journal of Gynecology & Obstetrics, 2011
Objective: To identify differences in the management and outcome of patients with central nervous system metastases from epithelial ovarian cancer. Methods: The clinical and pathologic characteristics, treatment, and outcome of 23 patients with brain metastases from epithelial ovarian cancer who were treated during 1982-1994 were compared with those of 20 patients treated during 1995-2010 at the same center. Results: No differences were found in terms of primary tumor characteristics, time interval from ovarian cancer diagnosis to brain involvement diagnosis, sites of metastasis, and presence of extracranial disease. The main difference between the 2 groups was the therapeutic approach. During 1982-1994, most patients received radiotherapy only, whereas most patients during 1995-2010 underwent surgical resection followed by radiotherapy and/ or chemotherapy. The duration of survival during 1982-1994 was 5 months, which was significantly shorter than the duration of survival (18 months) during 1995-2010. Conclusion: An aggressive multimodal treatment approach might prolong the survival of patients with brain involvement from ovarian cancer. . Their clinical and pathologic characteristics-including age at diagnosis of the primary tumor, histology, grading, and stage of the primary tumor according to the International Federation of Gynecology and Obstetrics (FIGO), clinical course, time until diagnosis of brain metastases, age at the time of diagnosis of the metastases, site and number of the metastases, presence of extracranial disease, type of treatment, and time and cause of death-were reviewed. The study was approved by
Brain metastasis as a late manifestation of ovarian carcinoma
European Journal of Cancer Care, 2011
Brain metastasis as a late manifestation of ovarian carcinoma This paper aims to evaluate the clinical characteristics of ovarian cancer patients with cerebral metastases. Ten ovarian cancer patients with brain metastases were retrospectively identified from a total of 539 ovarian cancer patients. Their characteristics before and at the time of diagnosis of cerebral metastases were analysed. The survival of them was also measured. Ten (1.9%) of the 539 ovarian cancer patients had brain metastases in the study period. Nine had stage III or IV tumours with either moderate or poor histological differentiation. The mean time from diagnosis of ovarian cancer to documentation of central nervous system metastasis was 24.3 months, which was 11.1 months if other sites of metastasis were involved before cerebral relapse. All of the patients with intra-cranial tumours suffered from associated neurological defects and relived by treatments. The median survival time after diagnosis of central nervous system involvement was 3 months. In this study, all ovarian cancer patients with cerebral metastases had clinical neurological symptoms. Physicians should pay more attention to ovarian cancer patients with neurological defects and arrange brain imaging studies for the early diagnosis of brain metastases and prompt management to improve quality of life.
Brain metastasis from ovarian cancer: case report and review of the literature
Medical Oncology
We present an 80-year-old lady with a history of ovarian cancer, who manifested with seizure and left upper extremity weakness. The imaging revealed a multilobulated mass within right parietal lobe. She underwent surgical resection and the pathology was compatible with metastasis from ovarian adenocarcinoma. She received a whole brain radiation therapy and she has been in remission for more than 2 years.
Brain Metastases in a Patient with Ovarian Cancer
International Journal of Neurologic Physical Therapy, 2017
Brain metastases are associated with a poor prognosis. Depending on the patient's age, functional status, extent of systemic disease, and number of metastases. We report a case of 22-year-old female who presented with 2 months history of headache and vomiting and 1 day history of not communicating, neck stiffness, and generalized body weakness. Patient has been unwell for 2 months after she had collapsed at school 2 months prior complaining of severe headache, she allegedly stroked one month prior with left sided weakness. No history of trauma and seizures but had history of falling and remaining unconscious for unspecified period of time. No history of chronic illness and no family history of malignancies. Brain CT scan and MRI documented multiple lobulated irregularly enhancing brain parenchymal mass lesions of variable sizes, patient was taken to theatre and burr hole for brain tumor biopsy was done and specimen taken for histology which confirmed metastatic carcinoma and the tumor immunoreacted negatively to TTF1 and positively to CK7. Treatment of brain metastasis has evolved over the years from WBRT only for most patients to multimodal therapy including surgical resection, if feasible, followed by Whole brain Radiotherapy (WBRT) and/or chemotherapy.